 Spinal muscular atrophy or SMA affects 30 families across Australia annually and it's known as a progressive peripheral nerve disease which causes muscle weakness and wasting and its severe forms of life limiting. A newborn screening for SMA pilot commenced in New South Wales in the ACT in 2018 and this study compares two cohorts pre and post newborn screening across a rapidly changing diagnostic and therapeutic landscape to figure out whether newborn screening for this condition is clinically impactful.